Congressional Biosimilar Pathway Sponsors Use Letter-Writing Campaign To End Exclusivity Confusion
Executive Summary
Seven congressional sponsors of the legislation that established FDA's biosimilars approval pathway are weighing in with the agency about how it should implement it.
You may also be interested in...
Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?
Rising concerns among generic firms about how FDA will interpret biosimilar exclusivity provisions may have escalated due to fears about the consequences of increased congressional scrutiny of the new pathway.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.